

# Pharmacokinetics and drug bioavailability

Jake Bundy

Biomolecular Medicine

Surgery and Cancer, Faculty of Medicine

# Learning objectives

- Understand what is meant by pharmacokinetics
- Be able to define bioavailability
- Be able to describe factors that affect drug bioavailability, for both biological (patient-specific) and chemical (drug-specific) factors

# Pharmacokinetics:

## The journey of a drug through the body

To achieve its effect a drug must first be presented in a suitable formulation at an appropriate site of **ADMINISTRATION** and then (usually) **ABSORBED** and **DISTRIBUTED** through the body to its site of action. For the effect to wear off the drug must almost always be **METABOLISED** and/or **EXCRETED** with these residues being **VOIDED (REMOVED)** from the body.

# Pharmacokinetics: The journey of a drug through the body (ADME)

ADMINISTRATION

**A**BSORPTION

**D**ISTRIBUTION

**M**ETABOLISM

**E**XCRETION

REMOVAL

# Pharmacokinetics

- **The variation with time of the drug concentration in the blood (or plasma).**
- **There are a number of derived parameters that describe the drug's journey through the body.**

## **Bioavailability**

Proportion of the administered drug that is available within the body to exert its pharmacological effect

# Pharmacokinetics

## Apparent volume of distribution

The volume in which a drug appears to be distributed  
- an indicator of the pattern of distribution

$$V_D = [\text{drug}]_{\text{total}} / [\text{drug}]_{\text{plasma}}$$

Low values: high plasma concentration, e.g. because of protein binding


High values: e.g. fat-soluble drug sequestered into lipids

# Pharmacokinetics

## **Biological half-life**


Time taken for the concentration of drug (in blood/plasma) to fall to half its original value

# Pharmacokinetics






# Pharmacokinetics



# Pharmacokinetics



Bioavailability:  
fraction of drug that is  
absorbed.  $F$

$$\frac{(\text{AUC}_{\text{iv}} \times \text{dose}_0)}{(\text{AUC}_0 \times \text{dose}_{\text{iv}})}$$

# Pharmacokinetics:

## The journey of a drug through the body

### Summary

- To achieve its effect a drug must first be presented in a suitable formulation at an appropriate site of **ADMINISTRATION**.
- The drug is then (usually) **ABSORBED** and **DISTRIBUTED** through the body to its site of action.
- For the effect to wear off the drug must almost always be **METABOLISED** and/or **EXCRETED**.
- Finally the drug residues are **VOIDED (REMOVED)** from the body.

# Drug Administration

Drug actions may be...

**SYSTEMIC** - the entire organism

**LOCAL** – restricted to one area of the organism

# Drug administration routes

## **ENTERAL ROUTES**

sublingual, buccal, oral, rectal

## **PARENTERAL ROUTES**

intravenous, intramuscular, subcutaneous,  
percutaneous, inhalation

# Drug Absorption

Drugs have to traverse both aqueous and lipid environment

Lipid soluble drugs (e.g. anaesthetics)

usually small volatile molecules that 'dissolve' into membranes

Water soluble drugs (e.g. most drugs)

usually weak acids or bases able to become charged – ionisation depends on pKa of the molecule and the pH of the medium


# Drug absorption

Transfer across membranes...

- Passive diffusion (most common – pH partition hypothesis)
- Facilitated diffusion
- Active transport (important in drug excretion)
- Pinocytosis (phagocytosis-like mechanism)
- Filtration (small water-soluble molecules)
- Paracellular transport (around cells)

# Drug absorption

Passive diffusion – The pH Partition Hypothesis





# Effects of lipophilicity

Octanol/water partition coefficient:  $\log K_{ow}$ ,  $\log P$

Widely used in quantitative structure-activity relationship (QSAR) modelling


- attempt to predict activity – including uptake
- Uptake dominated by  $\log P$  term
- $\log P$  can be measured or calculated (based on a fragment principle)

# Effects of lipophilicity

Octanol/water partition coefficient:  $\log K_{ow}$ ,  $\log P$

Widely used in quantitative structure-activity relationship (QSAR) modelling


- Gives a non-linear (“quadratic”) relationship



# Effects of lipophilicity

Log P can be replaced by log D, which takes ionization status into account

Flat part of curve:  $\log D = \log P$  of neutral species



# An example: aspirin

$pK_a$  is about 3.5.

what is stomach pH?

Aspirin is essentially near-completely ionized

Henderson-Hasselbalch equation:  $pH = pK_a + \log(A^-/HA)$


Absorbed in stomach – but transit time is fast!

When would you use soluble aspirin, and when would you use enteric-coated aspirin?

Soluble: rapid pain relief; enteric-coated: slow release

N Engl J Med 343:863, September 21, 2000,  
Images in Clinical Medicine

*An Aspirin Tablet and a Gastric Ulcer*



# Effects of formulation

Drug formulation – what options are there?

e.g. for oral route: tablets, gelatin capsules, syrup/  
tincture

Excipients

– why are they used? For stability, bulk, taste,  
performance

– what are they? e.g. Solid formulations: sucrose,  
lactose, talc, chalk, salts.

Liquid formulations: water, alcohol

# Drug distribution

Factors influencing drug distribution...

- Regional blood flow
- Extracellular binding (Plasma-protein binding)
- Capillary permeability (tissue alterations – renal, hepatic, brain/CNS, placental)
- Localisation in tissues

# Drug excretion

**In man there are two major routes of drug excretion...**

## **Kidney**

ultimately responsible for the elimination of most drugs

## **Liver**

some drugs are concentrated in the bile (usually large molecular weight conjugates)



# What other things affect bioavailability?

- Gastric motility
- Individual differences (pharmacogenomics)
- Diseases of absorption
- Diseases which affect blood flow
- First-pass metabolism

# When does a drug not need to be bioavailable?

- Non-systemic (topical) administration – e.g. to GI tract, skin creams, inhalation
- Pro-drugs: require metabolism to be active

# Toxicity versus effectiveness

Two very important parameters for a drug:

## **Therapeutic index and therapeutic window**

Therapeutic index =  $TD_{50} / ED_{50}$

Therapeutic window: “The range between the lowest dose that has a positive effect, and the highest dose before toxic effects outweigh the therapeutic effect.”

# Nutritional bioavailability

Nutritional bioavailability is not defined as strictly as for drug bioavailability – e.g. it may not be possible to carry out i.v. studies

# An example: selenium supplements

Why might we want to take selenium? [Anti-cancer effects](#)

What governs our natural selenium intake? [Soil Se \(affects food Se\)](#)

What is the active form of selenium in the body? [SeCys](#)

What is the commonest form of selenium found in the body? [Depends!](#)

What form of selenium is administered in supplements? [Very variable](#)

**Why is it important to know all this for selenium?** [‘Therapeutic index’ is low – lowest of any mineral](#)

# An example: selenium supplements

Nutritional bioavailability is not defined as strictly as for drug bioavailability – not possible to carry out i.v. studies for Se!

- about 70% of studies use total tissue Se levels
- about 10% of studies use stable Se isotope ratios

It is a very complex question, with no consensus answer! But:

- SeMet is more available than inorganic Se
- Methylated Se may be more effective in anti-cancer pathways